Aktuellt
SENASTE
Q-linea has secured a US FDA approval, which is positive. We look forward to Q-linea providing an update and more details regarding the US launch. Q-linea has limited financial flexibility and natural questions and alternatives could include a targeted regional launch, possibly with a commercial partner. We have not made any changes at this stage, and our later Base Case ahead of Q1 is SEK 6 (Bull 20 and Bear SEK 1). Q-linea has scheduled the Q1 report to May 17th 2024.
LÄS MER
